References
1. Soriani S, Mura C, Panico AR, et
al. Rapid detection of t (15; 17)(q24; q21) in acute promyelocytic
leukaemia by microwave‐assisted fluorescence in situ hybridization.
Hematological Oncol. 2017;35(1):94-100.
2. Iland HJ, Bradstock K, Supple SG,
et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as
initial therapy in acute promyelocytic leukemia (APML4).Blood, J Am Soc
Hematol. 2012;120(8):1570-80.
3. Warrell Jr RP, de The H, Wang Z-Y,
et al. Acute promyelocytic leukemia. N Engl J Med. 1993;329(3):177-89.
4. Sakuragawa N, Takahashi K,
Hoshiyama M, et al. Pathologic cells as procoagulant substance of
disseminated intravascular coagulation syndrome in acute promyelocytic
leukemia. Thromb Res. 1976;8(3):263-73.
5. Kentos A, Moine FL, Crenier L, et
al. All-Trans retinoic acid-induced thrombocytosis in a patient with
acute promyelocytic leukaemia. Br J Haematol, 1997;9(97): 685-692.
6. Tallman MS, editor.
All-trans-retinoic acid in acute promyelocytic leukemia and its
potential in other hematologic malignancies. Semin Hematol; 1994; 31(4
Suppl 5):38-48.
7. Grimwade D, Biondi A, Mozziconacci
M-J, et al. Characterization of acute promyelocytic leukemia cases
lacking the classic t (15; 17): results of the European Working Party.
Blood, J Am Soc Hematol. 2000;96(4):1297-308.
8. Schnittger S, Bacher U, Haferlach
C, et al. Clinical impact of FLT3 mutation load in acute promyelocytic
leukemia with t (15; 17)/PML-RARA. Haematologica. 2011;96(12):1799-807.
9. Williams W. Secondary
thrombocytosis. Williams Hematol 5th ed New York: Mc-Graw-Hill Inc.
1995:1361-3.
10. Lo-Coco F, Avvisati G, Vignetti
M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic
leukemia. N Engl J Med. 2013;369:111-21.
11. Osman AE, Anderson J, Churpek JE,
et al. Treatment of acute promyelocytic leukemia in adults. J Oncol
Prac. 2018;14(11):649-57.
12. Burnett AK, Russell NH, Hills RK,
et al. Arsenic trioxide and all-trans retinoic acid treatment for acute
promyelocytic leukaemia in all risk groups (AML17): results of a
randomised, controlled, phase 3 trial. Lancet Oncol.
2015;16(13):1295-305.
13. Platzbecker U, Avvisati G,
Cicconi L, et al. Improved outcomes with retinoic acid and arsenic
trioxide compared with retinoic acid and chemotherapy in non-high-risk
acute promyelocytic leukemia: final results of the randomized
Italian-German APL0406 trial 2017: Am Soc Clin Oncol.
14. Losada R, Espinosa E, Hernandez
C, et al. Thrombocytosis in patients with acute promyelocytic leukaemia
during all‐trans retinoic acid treatment. Br J Haematol.
1996;95(4):704-5.
15. Aldapt MB, Kassem N, Al-Okka R,
et al. Thrombocytosis in a male patient with acute promyelocytic
leukaemia during all-trans retinoic (ATRA) acid treatment. Acta Bio
Medica: Atenei Parmensis. 2018;89(3):33.
16. Harker LA. Control of platelet
production. Annual Rev Med. 1974;25(1):383-400.
17. Qian S, Fu F, Li W, et al.
Primary role of the liver in thrombopoietin production shown by
tissue-specific knockout. Blood, Journal Am Soc Hematol.
1998;92(6):2189-91.
18. Degos L, Dombret H, Chomienne C,
et al. All-trans-retinoic acid as a differentiating agent in the
treatment of acute promyelocytic leukemia. Blood. 1995; 85 (10):
2643–2653.